Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications
about
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitisCirculating immune cells in multiple sclerosis.Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis PatientsModulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Role of Atypical Chemokine Receptors in Microglial Activation and Polarization.The effect of 1, 25(OH)2 D3 (calcitriol) alone and in combination with all-trans retinoic acid on ROR-γt, IL-17, TGF-β, and FOXP3 gene expression in experimental autoimmune encephalomyelitis.A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE.Casein kinase 2 is a critical determinant of the balance of Th17 and Treg cell differentiationThe sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis.Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.The Cerebellum of Patients with Steatohepatitis Shows Lymphocyte Infiltration, Microglial Activation and Loss of Purkinje and Granular Neurons.Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q28067738-3C1EAF56-D42E-4B34-9DEB-EFF32EEADB51Q30242026-0B739F94-2432-415C-8687-A717271A06BEQ37171985-661008D2-75FB-4072-9136-49855BC54335Q38774697-7F1BD486-674B-446A-8AB3-5FB2A5CB6E64Q39365708-93098279-8C2B-4139-898D-4C1EBABF27B9Q40416300-53F7A982-CA85-47F6-9ECD-CAF4D1EA290CQ41549202-5B92EEFC-3B91-433D-A0F2-F73A0087B16EQ42370428-ED8DEA8F-8D8E-478E-A5F9-29128457570FQ45066717-A7C0021A-24B7-4353-AAAD-65C62441D9F7Q47139579-F7E8389E-AEA8-4882-81A6-727B26EECB4EQ55258910-706B6389-0F33-4F17-BA37-CCCE5B406A5CQ55287599-7AD5BB5E-E5A5-44CB-9B3F-5A25F4E192BFQ58555322-2EBCA3F3-48D8-43FB-9D8C-488C73106284
P2860
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@ast
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@en
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@nl
type
label
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@ast
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@en
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@nl
prefLabel
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@ast
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@en
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@nl
P2093
P2860
P921
P3181
P356
P1476
Th17 Cells Pathways in Multipl ...... l and Therapeutic Implications
@en
P2093
Giordani Rodrigues Dos Passos
Jefferson Becker
Kazuo Fujihara
P2860
P304
P3181
P356
10.1155/2016/5314541
P407
P50
P5008
P577
2016-01-28T00:00:00Z